Sarepta appoints former AbbVie R&D chief Michael Severino as new CEO amid DMD regulatory outlook

Sarepta Therapeutics announced that Michael Severino, who previously led Tessera Therapeutics and served as AbbVie’s head of research and development, will become the company’s chief executive. Severino will assume the role on Tuesday, succeeding Doug Ingram, who is retiring after nearly a decade at the helm.

Ingram’s departure comes as Sarepta awaits two pivotal regulatory decisions for its Duchenne muscular dystrophy programs. In a personal note, Ingram disclosed that two family members have been diagnosed with myotonic dystrophy, a condition for which Sarepta is collaborating with Arrowhead Therapeutics on a potential treatment.

The board highlighted Severino’s broad industry experience, strategic vision, and track record of building successful franchises across therapeutic areas. Following the announcement, Sarepta’s stock rose about 5.5%, reflecting investor confidence in the leadership transition and the company’s ongoing scientific progress.